Iqvia (IQV) PT Set at $120.00 by Mizuho

Iqvia (NYSE:IQV) has been given a $120.00 target price by stock analysts at Mizuho in a research report issued to clients and investors on Monday, August 6th. The firm currently has a “hold” rating on the medical research company’s stock. Mizuho’s price target points to a potential downside of 5.58% from the company’s previous close.

Several other brokerages have also recently weighed in on IQV. Piper Jaffray Companies reissued a “hold” rating and set a $97.00 price target on shares of Iqvia in a research report on Wednesday, July 25th. SunTrust Banks upped their target price on shares of Iqvia to $140.00 and gave the company a “buy” rating in a research report on Wednesday, July 25th. Royal Bank of Canada reaffirmed a “buy” rating and issued a $129.00 target price on shares of Iqvia in a research report on Wednesday, July 25th. Bank of America raised shares of Iqvia from a “neutral” rating to a “buy” rating and set a $135.00 target price on the stock in a research report on Wednesday, July 25th. Finally, Stifel Nicolaus increased their price target on shares of Iqvia from $128.00 to $150.00 and gave the stock a “buy” rating in a research report on Wednesday, July 25th. Five investment analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Iqvia presently has a consensus rating of “Buy” and a consensus target price of $126.79.

Shares of Iqvia stock traded up $1.18 during trading hours on Monday, reaching $127.09. 727,600 shares of the company’s stock were exchanged, compared to its average volume of 1,263,960. Iqvia has a 1 year low of $91.57 and a 1 year high of $127.28. The firm has a market capitalization of $25.64 billion, a price-to-earnings ratio of 29.08, a PEG ratio of 1.82 and a beta of 0.72. The company has a quick ratio of 1.13, a current ratio of 1.13 and a debt-to-equity ratio of 1.40.

Iqvia (NYSE:IQV) last released its earnings results on Tuesday, July 24th. The medical research company reported $1.29 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.14 by $0.15. The business had revenue of $2.57 billion during the quarter, compared to analyst estimates of $2.50 billion. Iqvia had a net margin of 12.68% and a return on equity of 13.51%. The business’s revenue was up 9.0% compared to the same quarter last year. research analysts anticipate that Iqvia will post 5.13 EPS for the current fiscal year.

In related news, major shareholder Cpp Investment Board Private H sold 9,291,036 shares of the stock in a transaction on Friday, June 15th. The stock was sold at an average price of $103.00, for a total transaction of $956,976,708.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Robert Parks sold 871 shares of the stock in a transaction on Thursday, August 2nd. The stock was sold at an average price of $124.34, for a total value of $108,300.14. The disclosure for this sale can be found here. Insiders sold 11,201,623 shares of company stock valued at $1,160,990,595 over the last three months. Corporate insiders own 6.00% of the company’s stock.

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Steward Partners Investment Advisory LLC lifted its holdings in Iqvia by 19.4% in the second quarter. Steward Partners Investment Advisory LLC now owns 2,933 shares of the medical research company’s stock valued at $293,000 after acquiring an additional 476 shares during the period. Louisiana State Employees Retirement System lifted its holdings in Iqvia by 6.7% in the second quarter. Louisiana State Employees Retirement System now owns 9,500 shares of the medical research company’s stock valued at $948,000 after acquiring an additional 600 shares during the period. AMP Capital Investors Ltd lifted its holdings in Iqvia by 1.3% in the second quarter. AMP Capital Investors Ltd now owns 48,272 shares of the medical research company’s stock valued at $4,818,000 after acquiring an additional 600 shares during the period. Private Capital Group LLC lifted its holdings in Iqvia by 177.0% in the first quarter. Private Capital Group LLC now owns 1,061 shares of the medical research company’s stock valued at $104,000 after acquiring an additional 678 shares during the period. Finally, Howard Capital Management lifted its holdings in Iqvia by 0.6% in the second quarter. Howard Capital Management now owns 125,625 shares of the medical research company’s stock valued at $12,540,000 after acquiring an additional 710 shares during the period. 91.98% of the stock is owned by hedge funds and other institutional investors.

About Iqvia

IQVIA Holdings Inc provides integrated information and technology-enabled healthcare services in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Commercial Solutions, Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offers a range of cloud-based applications and related implementation, real-world insights, and reference information services; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services.

See Also: Trading Strategy Methods for Individual Investors

Analyst Recommendations for Iqvia (NYSE:IQV)

Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply